Investors.com http://ift.tt/1HGQ9mE Call it a jack of all trades in biotech. Rather than just target a small number of drug therapies, Ligand Pharmaceuticals (LGND) focuses on a broad range of assets that address a host of diseases: multiple myeloma, hepatitis, Alzheimer's, diabetes, anemia, osteoporosis and many others. "We do early-stage development, and we aim to partner early," said Matt Foehr, president and chief operating officer. "We keep a flat operating structure, and we
No comments:
Post a Comment